Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMune names new CSO
Dr Dougherty has a doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine. Boris Reznik, chairman of OncoMune, said: “Dr Dougherty has
Dr Dougherty has a doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine. Boris Reznik, chairman of OncoMune, said: “Dr Dougherty has
The Phase II, multi-center, international randomized, double-blind, placebo-controlled study (Mpex 204) is expected to enroll 140 stable cystic fibrosis (CF) patients to evaluate the safety, tolerability and efficacy
Ranbaxy believes that it has first-to-file status on Valganciclovir tablets, thereby providing a potential of 180-days of marketing exclusivity, offering a significant opportunity in the future. Valganciclovir HCl
These rights enable Pharming to accelerate pharmaceutical development of recombinant human fibrinogen (rhFIB) and stimulate medical device development through its biomaterials program. Pharming has obtained exclusive licenses on
This study is a component of an initial stage of at least 10 Phase I and II clinical trials of IMC-A12 sponsored by the cancer therapy evaluation program
Approximately 21 patient and consumer organizations (PCOs) participated in European Medicines Agency (EMEA) activities in 2007 and more than 92% of their representatives expressed satisfaction at the EMEA
The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received
The company expects its Phase I/II clinical study for prevention or treatment of delayed graft function (DGF) in kidney transplant patients to begin in the second half of
The grant will help fund continuing experiments directed towards the development and commercialization of novel, automated, and reproducible methods for the extraction of clinically important protein biomarkers, subcellular
The protective effect of progesterone in treating brain injury has been firmly established but the inability to develop a product that can be used in the field by